|
Synonyms: AVE-1642 | AVE1642 | Lumvoa®: | veligrotug-vvze | VRDN-001
veligrotug is an approved drug
Compound class:
Antibody
Comment: Veligrotug (AVE-1642) is a monoclonal antibody that targets insulin-like growth factor 1 receptor (IGF1R) [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Girnita L, Smith TJ, Janssen JAMJL. (2022)
It Takes Two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. J Clin Endocrinol Metab, 107 (Suppl_1): S1-S12. [PMID:35167695] |
|
2. Iams WT, Lovly CM. (2015)
Molecular Pathways: Clinical Applications and Future Direction of Insulin-like Growth Factor-1 Receptor Pathway Blockade. Clin Cancer Res, 21 (19): 4270-7. [PMID:26429980] |
|
3. Kamboj A, Harrison AR, Mokhtarzadeh A. (2023)
Emerging therapies in the medical management of thyroid eye disease. Front Ophthalmol (Lausanne), 3: 1295902. [PMID:38983101] |
|
4. Kaplan R, Zhao Y, Tsai J, Dickinson B, Swanson T, Foster K, Bedian V. (2025)
Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs, 17 (1): 2585616. [PMID:41250603] |
|
5. Krieger CC, Sui X, Kahaly GJ, Neumann S, Gershengorn MC. (2022)
Inhibition of TSH/IGF-1 Receptor Crosstalk by Teprotumumab as a Treatment Modality of Thyroid Eye Disease. J Clin Endocrinol Metab, 107 (4): e1653-e1660. [PMID:34788857] |
|
6. Latif R, Mezei M, Davies TF. (2025)
Mechanisms in Thyroid Eye Disease: The TSH Receptor Interacts Directly With the IGF-1 Receptor. Endocrinology, 166 (2). [PMID:39821041] |
|
7. McGuigan A. (2026)
Veligrotug: First Approval. Drugs, [Epub ahead of print]. [PMID:42864578] |
|
8. Scagliotti GV, Novello S. (2012)
The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev, 38 (4): 292-302. [PMID:21907495] |
|
9. Smith TJ. (2025)
Thyroid eye disease and the IGF-1 receptor. Lancet Diabetes Endocrinol, 13 (9): 741-742. [PMID:40812955] |
|
10. Sohail A, Mushtaq A, Iftikhar A, Warraich Z, Kurtin SE, Tenneti P, McBride A, Anwer F. (2018)
Emerging immune targets for the treatment of multiple myeloma. Immunotherapy, 10 (4): 265-282. [PMID:29421983] |
|
11. Yen MT, Cockerham K, Saeed P, Leibowitz S, Mudumbai RC, Schittkowski MP, Lee V, Abrams J, Turbin RE, Pío-Rendón JB et al.. (2026)
THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. Ophthalmology, [Epub ahead of print]. [PMID:42223386] |